Ivo Veletic, M.D.
Department of Leukemia, Division of Cancer Medicine
Present Title & Affiliation
Primary Appointment
Instructor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Dual/Joint/Adjunct Appointment
Instructor, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas
Research Interests
Selected ongoing and recently completed research projects that I lead or co-lead:
- As a Principal Investigator, I have been leading a project supported by the Bone Disease Program of Texas (10/14/2021 – 10/13/2022), aimed at delineating the role of the JAK-STAT pathway in the induction of osteosclerosis in MF. In this project, our team is investigating the effects of JAK2 mutation on osteoclast formation and function in vivo using mouse models, fluorescence-activated cell sorting, single-nuclei RNA sequencing, and multispectral tissue imaging.
- In another project where I serve as a Principal Investigator, we aim to characterize fibrocytes and mesenchymal stromal cells (MSCs) in the BM and extramedullary sites in MF. Our objective is to assess the distribution of these cells across different tissues in relation to collagen and reticulin fibrosis, using multiplexed tissue imaging, spatial analysis, cytokine profiling, and next-generation sequencing.
- As a Co-investigator, I am involved in a project led by Dr. Srdan Verstovsek, aimed at elucidating the molecular and functional states of macrophages in MF to identify novel therapeutic targets. The project employs a combination of cell cultures, mouse models, genome editing techniques, tissue imaging methods, single-cell DNA sequencing, and mass cytometry.
- I am also serving as a Co-investigator in a project led by Dr. Zeev Estrov, which focuses on characterizing the effects of CLL cell-derived exosomes on hematopoiesis and immune dysfunction in CLL. The project involves the use of exosome isolation techniques, flow cytometry, mass cytometry, electron and confocal microscopy, and RNA-seq.
- Additionally, I am a Co-investigator in a project led by Dr. Prithviraj Bose, aimed at investigating the clinical efficacy of the anti-SLAMF7 monoclonal antibody elotuzumab in MF patients (NCT04517851) and identifying its effects on BM fibrocytes and BM fibrosis, circulating monocytes, and plasma cytokines. Our team will perform quantitative tissue imaging, mass cytometry, and cytokine profiling analyses in this project.
Clinical Interests
N/A
Education & Training
Degree-Granting Education
| 2014 | University of Zagreb School of Medicine, Zagreb, HR, Medicine, Doctor of Medicine (M.D.) |
Postgraduate Training
| 2022-2023 | Leadership Training, LEADing Others Core Curriculum, MD Anderson Leadership Institute / American Association for Physician Leadership, Houston, TX |
| 2015-2020 | Postdoctoral Fellowship, Hematology/Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX |
| 2014-2015 | Clinical Internship, Clinical Medicine, Croatian Health Insurance Fund / Neuropsychiatric Hospital Dr. Ivan Barbot, Zagreb |
Board Certifications
| 2015 | Croatia Medical Licensing Examination |
Experience & Service
Other Appointments/Responsibilities
Student Assistant, Clinical Propedeutics, University Hospital Dubrava, Zagreb, 2012 - 2014
Honors & Awards
| 2021 | Rolanette and Berdon Lawrence Research Award, Baylor College of Medicine / MD Anderson / UTHealth Bone Disease Program of Texas |
| 2013 | Special Dean’s Award, University of Zagreb School of Medicine, Croatia |
| 2010 | Special Rector’s Award, University of Zagreb, Croatia |
| 2007 | National Scholarship, Ministry of Science and Education, Croatia |
Professional Memberships
Selected Publications
Peer-Reviewed Articles
- Dasdemir E, Veletic I, Ly C, Quesada AE, Pacheco CD, Jelloul FZ, Borges P, Basu S, Jindal S, Wang Z, Lazar A, Wani KM, Antunes DA, Reville PK, Gunaratne PH, Tower RJ, Sharma P, Abbas HA. Spatial Transcriptomics Reveals Inflammation and Trans-differentiation States of Acute Myeloid Leukemia in Extramedullary and Medullary Tissues. Hemasphere. e-Pub 2024.
- Veletic I, Harris DM, Rozovski U, Bertilaccio MTS, Calin G, Takahashi K, Li P, Liu Z, Manshouri T, Drula RC, Furudate K, Muftuoglu M, Hossain A, Hossain WG, Keating MJ, Estrov Z. CLL cell-derived exosomes alter the immune and hematopoietic systems. Leukemia. e-Pub 2024.
- Ly C, Veletic I, Pacheco C, Dasdemir E, Jelloul F, Ferri-Borgongo S, Basi A, Gomez J, Root J, Reville P, Jindal S, Basu S, Sharma P, Quesada A, Bueso-Ramos C, Manshouri T, Cuglievan B, Garcia M, Burks J, Abbas H. Multimodal Spatial Proteomic Profiling in Acute Myeloid Leukemia Running Title: Spatial Proteomics in Acute Myeloid Leukemia. NPJ Precis Oncol. e-Pub 2024.
- Wang B*, Reville PK*, Yassouf Y, Jelloul FZ, Ly C, Desai PN, Wang Z, Borges P, Veletic I, Dasdemir E, Burks JK, Tang G, Guo S, Garza AI, Nasnas C, Vaugh NR, Baran N, Deng Q, Matthews J, Gunaratne PH, Antunes DA, Ekmekcioglu S, Sasaki K, Garcia M, Cuglievan B, Hao D, Daver N, Green MR, Konopleva M, Futreal A, Post AM, Abbas HA. Comprehensive characterization of IFNγ signaling in acute myeloid leukemia reveals prognostic and therapeutic strategies. Nat Commun 15(1):1821, 2024. e-Pub 2024. PMID: 38418901.
- Verstovsek S, Foltz L, Gupta V, Hasserjian R, Manshouri T, Mascarenhas J, Mesa R, Pozdnyakova O, Ritchie E, Veletic I, Gamel K, Hamidi H, Han L, Higgins B, Trunzer K, Uguen M, Wang D, El-Galaly TC, Todorov B, Gotlib J. Safety and efficacy of zinpentraxin alfa as monotherapy or in combination with ruxolitinib in myelofibrosis: stage I of a phase II trial. Haematologica 108(10):2730-2742, 2023. e-Pub 2023. PMID: 37165840.
- Rozovski U*, Veletic I*, Harris DM, Li P, Liu Z, Jain P, Manshouri T, Ferrajoli A, Burger JA, Bose P, Thompson PA, Jain N, Wierda WG, Verstovsek S, Keating MJ, Estrov Z. STAT3 Activates the Pentraxin 3 Gene in Chronic Lymphocytic Leukemia Cells. J Immunol 208(12):2847-2855, 2022. e-Pub 2022. PMID: 35595309.
- Manshouri T*, Veletic I*, Li P, Yin CC, Post SM, Verstovsek S, Estrov Z. GLI1 activates pro-fibrotic pathways in myelofibrosis fibrocytes. Cell Death Dis 13(5):481, 2022. e-Pub 2022. PMID: 35595725.
- Veletic I*, Prijic S*, Manshouri T, Nogueras-Gonzalez GM, Verstovsek S, Estrov Z. Altered T-cell subset repertoire affects treatment outcome of patients with myelofibrosis. Haematologica 106(9):2384-2396, 2021. e-Pub 2021. PMID: 32732359.
- Rozovski U, Harris DM, Li P, Liu Z, Jain P, Manshouri T, Veletic I, Ferrajoli A, Bose P, Thompson P, Jain N, Verstovsek S, Wierda W, Keating MJ, Estrov Z. STAT3 induces the expression of GLI1 in chronic lymphocytic leukemia cells. Oncotarget 12(5):401-411, 2021. e-Pub 2021. PMID: 33747356.
- Manshouri T, Verstovsek S, Harris DM, Veletic I, Zhang X, Post SM, Bueso-Ramos CE, Estrov Z. Primary myelofibrosis marrow-derived CD14+/CD34- monocytes induce myelofibrosis-like phenotype in immunodeficient mice and give rise to megakaryocytes. PLoS One 14(9):e0222912, 2019. e-Pub 2019. PMID: 31569199.
- Veletic I, Manshouri T, Multani AS, Yin CC, Chen L, Verstovsek S, Estrov Z. Myelofibrosis osteoclasts are clonal and functionally impaired. Blood 133(21):2320-2324, 2019. e-Pub 2019. PMID: 30745304.
- Lucijanic M, Veletic I, Rahelic D, Pejsa V, Cicic D, Skelin M, Livun A, Tupek KM, Stoos-Veic T, Lucijanic T, Maglicic A, Kusec R. Assessing serum albumin concentration, lymphocyte count and prognostic nutritional index might improve prognostication in patients with myelofibrosis. Wien Klin Wochenschr 130(3-4):126-133, 2018. e-Pub 2018. PMID: 29372410.
- Rozovski U, Harris DM, Li P, Liu Z, Jain P, Veletic I, Ferrajoli A, Burger J, Thompson P, Jain N, Wierda W, Keating MJ, Estrov Z. Activation of the B-cell receptor successively activates NF-κB and STAT3 in chronic lymphocytic leukemia cells. Int J Cancer 141(10):2076-2081, 2017. e-Pub 2017. PMID: 28722170.
- Rozovski U, Harris DM, Li P, Liu Z, Jain P, Veletic I, Ferrajoli A, Burger J, O'Brien S, Bose P, Thompson P, Jain N, Wierda W, Keating MJ, Estrov Z. Constitutive Phosphorylation of STAT3 by the CK2-BLNK-CD5 Complex. Mol Cancer Res 15(5):610-618, 2017. e-Pub 2017. PMID: 28130399.
- Jain P, Keating M, Renner S, Cleeland C, Xuelin H, Gonzalez GN, Harris D, Li P, Liu Z, Veletic I, Rozovski U, Jain N, Thompson P, Bose P, DiNardo C, Ferrajoli A, O'Brien S, Burger J, Wierda W, Verstovsek S, Kantarjian H, Estrov Z. Ruxolitinib for symptom control in patients with chronic lymphocytic leukaemia: a single-group, phase 2 trial. Lancet Haematol 4(2):e67-e74, 2017. e-Pub 2017. PMID: 28089238.
Abstracts
- Dasdemir E, Veletic I, Ly CP, Quesada AE, Jelloul FZ, Borges P, Basu S, Jindal S, Wang Z, Lazar AJ, Wani KM, Antunes DA, Reville PK, Gunaratne P, Tower RJ, Sharma P, Abbas HA. Multimodal Spatial Transcriptomic Profiling Elucidates Niche-Specific Dynamics in Medullary and Extramedullary Acute Myeloid Leukemia. ASH Annual Meeting and Exposition 144(Suppl 1):1059, 2024. e-Pub 2024.
- Ly CP, Veletic I, Pacheco CD, Dasdemir E, Jelloul FZ, Ferri-Borgogno S, Basi A, Gomez JA, Root JL, Reville PK, Quesada AE, Bueso-Ramos CE, Garcia MB, Burks JK, Abbas HA. Multimodal Spatial Profiling in Acute Myeloid Leukemia. ASH Annual Meeting and Exposition 144(Suppl 1):2681, 2024. e-Pub 2024.
- Veletic I, Manshouri T, Yin CC, Pacheco CD, Ly CP, Dasdemir E, Cohen EN, Masarova L, Pemmaraju N, Bose P, Kantarjian HM, Estrov Z, Reville PK, Dunbar A, Abbas H. Temporal Dynamics of Bone Marrow Fibrocytes in the Progression of Primary Myelofibrosis. ASH Annual Meeting and Exposition 144(Suppl 1):1760, 2024. e-Pub 2024.
- Abbas HA, Nguyen A, Wang B, Chen M, Yang G, Lampson B, Erlich RL, Veletic I. Blood-Based Proteomics for Deeper Insights into Indolent Systemic Mastocytosis: The Pioneer Trial Experience. ASH Annual Meeting and Exposition 144(Suppl 1):6569, 2024. e-Pub 2024.
- Veletic I, Manshouri T, Pacheco CD, Yin CC, Zhang Y, Li P, Cohen EN, Gomez JA, Burks JK, Verstovsek S, Estrov Z. Neoplastic Monocyte-Derived Fibrocytes Induce Bone Marrow Fibrosis in Patients with Primary Myelofibrosis. ASH Annual Meeting and Exposition 142(Suppl 1):4516, 2023. e-Pub 2023.
- Veletic I, Harris DM, Rozovski U, Li P, Liu Z, Manshouri T, Bertilaccio MTS, Calin GA, Drula RC, Takahashi K, Furudate K, Muftuoglu M, Hossain A, Ferrajoli A, Burger JA, Jain N, Wierda WG, Verstovsek S, Keating MJ, Estrov Z. CLL Cell-Derived Exosomes Impair Immune Function and Normal Hematopoiesis in CLL. ASH Annual Meeting and Exposition 142(Suppl 1):3264, 2023. e-Pub 2023.
- Wang B, Reville PK, Jelloul FZ, Desai PN, Borges P, Ly C, Veletic I, Dasdemir E, Burks JK, Tang G, Guo S, Vaugh N, Baran N, Deng Q, Matthews J, Gunaratne P, Antunes DA, Ekmekcioglu S, Sasaki K, Garcia MB, Cuglievan B, Hao D, Daver N, Green MR, Konopleva MY, Futreal A, Post SM, Abbas HA. IFNγ Signaling in Acute Myeloid Leukemia Mediates Immunomodulation and Reveals Therapeutic Strategies. ASH Annual Meeting and Exposition 142(Suppl 1):2796, 2023. e-Pub 2023.
- Bose P, Masarova L, Pemmaraju N, Dobbins M, Jain N, Abbas H, Kornblau S, Maiti A, Veletic I, Manshouri T, Bledsoe S, Richie MA, Hall-Moore N, Zhou L, Wang X, Kantarjian H, Estrov Z, Verstovsek S. A pilot study of the anti-SLAMF7 monoclonal antibody, elotuzumab, in patients with myelofibrosis. EHA Annual Congress 7(S3):e5738496, 2023. e-Pub 2023.
- Ferri-Borgogno S, Gomez JA, Veletic I, Burks JK, Mok SC. Depicting spatially-resolved immune landscapes in long-term ovarian cancer survivors by imaging mass cytometry. AACR Special Conference: Tumor Immunology and Immunotherapy 10(Suppl 12):B31, 2022. e-Pub 2022.
- How JA, Dang M, Ferri-Borgogno S, Euscher E, Yates MS, Peng E, Patel SD, Burks JK, Veletic I, Gomez J, Lu K, Mok SC, Wang L, Jazaeri AA. Predictors of innate resistance to pembrolizumab in patients with microsatellite instability-high endometrial cancer. AACR Annual Meeting 82(Suppl 12):1248, 2022. e-Pub 2022.
- Rozovski U, Harris D, Li P, Liu Z, Manshouri T, Veletic I, Jain P, Ferrajoli A, Burger J, Bose P, Thompson P, Jain N, Verstovsek S, Wierda W, Keating M, Estrov Z. STAT3 Induces the Expression of GLI1 in Chronic Lymphocytic Leukemia Cells. SOHO Annual Meeting 21(Suppl 1):S322-S323, 2021. e-Pub 2021.
- Veletic I, Manshouri T, Li P, Yin CC, Post S, Verstovsek S, Estrov Z. GLI1 Promotes the Pro-Fibrotic Function of Monocyte-Derived Fibrocytes in Myelofibrosis. SOHO Annual Meeting 21(Suppl 1):230, 2021. e-Pub 2021.
- Rozovski U, Harris DM, Li P, Liu Z, Manshouri T, Veletic I, Jain P, Ferrajoli A, Burger JA, Bose P, Thompson PA, Jain N, Verstovsek S, Wierda WG, Keating MJ, Estrov ZE. Constitutively activated STAT3 induces the production of PTX3 that contributes to the induction of bone marrow reticulin fibrosis in patient with CLL. ASH Annual Meeting and Exposition 134(Suppl 1):3024, 2019. e-Pub 2019.
- Rozovski U, Harris DM, Li P, Liu Z, Manshouri T, Veletic I, Jain P, Ferrajoli A, Burger JA, Bose P, Thompson PA, Jain N, Verstovsek S, Wierda WG, Keating MJ, Estrov ZE. Constitutively Activated STAT3 Induces the Expression of Gli1 in Chronic Lymphocytic Leukemia Cells. ASH Annual Meeting and Exposition 134(Suppl 1):3018, 2019. e-Pub 2019.
- Manshouri T, Veletic I, Zhang Y, Bove JE, Li, Harris DM, Liu Z, Cohen EN, Verstovsek S, Estrov ZE. STAT3-Induced Gli1 Promotes the Differentiation and Maturation of Myelofibrosis Fibrocytes. ASH Annual Meeting and Exposition 134(Suppl 1):2961, 2019. e-Pub 2019.
- Yuan B, Ly S, Veletic I, Maldonado M, Zhou X, deCrombrugghe B, Andreeff M, Battula VL. Acute myeloid leukemia cells induce new bone formation by expanding osteoprogenitor niche in the bone marrow. AACR Annual Meeting 79(Suppl 13):2040, 2019. e-Pub 2019.
- Verstovsek S, Hasserjian RP, Pozdnyakova O, Veletic I, Mesa RA, Foltz L, Mascarenhas J, Ritchie EK, Palmer J, Silver RT, Kremyanskaya M, van den Blink B, Gupta R, Manshouri T, Yin CC, Estrov ZE, Gotlib JR. PRM-151 in Myelofibrosis: Efficacy and Safety in an Open Label Extension Study. ASH Annual Meeting and Exposition 132(Suppl 1):686, 2018. e-Pub 2018.
- Manshouri T, Veletic I, Yin CC, Chen L, Bove JE, Zhang Y, Verstovsek S, Estrov ZE. Bone Marrow Fibrocytes Overexpress Gli1 Oncogenic Transcription Factor in Primary Myelofibrosis. ASH Annual Meeting and Exposition 132(Suppl 1):1793, 2018. e-Pub 2018.
- Veletic I, Manshouri T, Nogueras González GM, Prijic S, Bove JE, Zhang Y, Verstovsek S, Estrov ZE. PD-1-Mediated T Cell Exhaustion Is Prevalent Among Patients with MPN-Associated Myelofibrosis Independent of JAK1/2 Inhibition. ASH Annual Meeting and Exposition 132(Suppl 1):5487, 2018. e-Pub 2018.
- Veletic I, Manshouri T, Newberry KJ, Bove JE, Zhang Y, Estrov Z, Verstovsek S. Increased Pentraxin-3 Correlates with the Activity of the Neoplastic Clone in Primary Myelofibrosis. ASH Annual Meeting and Exposition 130(Suppl 1):5284, 2017. e-Pub 2017.
- Rozovski U, Harris DM, Li P, Liu Z, Manshouri T, Veletic I, Bueso-Ramos C, Jain P, Verstovsek S, Ferrajoli A, Burger JA, Bose P, Thompson PA, Jain N, Wierda WG, Keating MJ, Estrov Z. CLL Cell-Derived Exosomes Promote Bone Marrow Fibrosis and Inhibit Normal Hematopoietic Colony Proliferation. ASH Annual Meeting and Exposition 130(Suppl 1):1728, 2017. e-Pub 2017.
- Veletic I, Manshouri T, Yin CC, Newberry KJ, Verstovsek S, Estrov Z. Neoplastic Monocyte-Derived Osteoclasts Are Highly Proliferative, but Sub-Functional in MPN-Associated Myelofibrosis. ASH Annual Meeting and Exposition 130(Suppl 1):1664, 2017. e-Pub 2017.
- Veletic I, Manshouri T, Prijic S, Yin CC, Bove JE, Zhang Y, Verstovsek S, Estrov Z. Multiplex Quantitative Imaging Analysis of Bone-Remodeling Cells in Patients with Myelofibrosis. ASH Annual Meeting and Exposition 128(22):4280, 2016. e-Pub 2016.
- Prijic S, Manshouri T, Veletic I, Newberry KJ, Zhang Y, Bove JE, Estrov Z, Verstovsek S. Loss of Normal T-Cell Subset Distribution in Myelofibrosis Is Recovered By the Immunomodulatory Effects of JAK1/2 Inhibition. ASH Annual Meeting and Exposition 128(22):3138, 2016. e-Pub 2016.
- Prijic S, Manshouri T, Zhang Y, Veletic I, Zhang X, Bove JE, Estrov Z, Verstovsek S. Ruxolitinib Treatment Induces a Transition of Classical to Non-Classical Monocytes in Patients with Myelofibrosis. ASH Annual Meeting and Exposition 126(23):2838, 2015. e-Pub 2015.
Letters to the Editor
- Veletic I, Manshouri T, Newberry KJ, Garnett J, Verstovsek S, Estrov Z. Pentraxin-3 plasma levels correlate with tumour burden and overall survival in patients with primary myelofibrosis. Br J Haematol 185: 382-386, 2019.
Selected Presentations & Talks
Local Presentations
- 2024. Spatiotemporal Mapping of Bone Marrow Dynamics in Myelofibrosis and Acute Myeloid Leukemia. Invited. Spatial Biology: Multiplex Multi-Omics Seminar. Houston, TX, US.
- 2019. Bone marrow beyond the complexity: Using high-dimensional imaging to understand myelofibrosis. Invited. CyTOF Mass Cytometry Annual User Group Meeting. Houston, TX, US.
- 2017. Quantitation of tissue remodeling cells in myelofibrosis. Invited. Molecular Hematology and Therapy Lab Meeting. Houston, TX, US.
Regional Presentations
- 2021. Role of the JAK-STAT pathway in the induction of osteosclerosis in myelofibrosis. Conference. Bone Disease Program of Texas Annual Retreat. Houston, TX, US.
International Presentations
- 2024. Temporal Dynamics of Bone Marrow Fibrocytes in the Progression of Primary Myelofibrosis. Poster. ASH Annual Meeting. San Diego, US.
- 2024. The Oncogenic Properties of CLL Cell-Derived Exosomes. Invited. CLL Global Alliance Meeting. Houston, US.
- 2023. Neoplastic Monocyte-Derived Fibrocytes Induce Bone Marrow Fibrosis in Patients with Primary Myelofibrosis. Poster. ASH Annual Meeting. San Diego, US.
- 2023. CLL Cell-Derived Exosomes Impair Immune Function and Normal Hematopoiesis in CLL. Poster. ASH Annual Meeting. San Diego, US.
- 2023. CLL cell-derived exosomes impair immune function and normal hematopoiesis in CLL. Invited. CLL Global Alliance Meeting. Houston, US.
- 2022. STAT3 Induces the Expression of PTX3 in CLL cells. Invited. CLL Global Alliance Meeting. Houston, US.
- 2021. GLI1 promotes the pro-fibrotic function of monocyte-derived fibrocytes in myelofibrosis. Poster. SOHO Annual Meeting. Houston, US.
- 2017. Neoplastic Monocyte-Derived Osteoclasts Are Highly Proliferative, but Sub-Functional in MPN-Associated Myelofibrosis. Poster. ASH Annual Meeting. Atlanta, US.
- 2016. Multiplex Quantitative Imaging Analysis of Bone-Remodeling Cells in Patients with Myelofibrosis. Poster. ASH Annual Meeting. San Diego, US.
Formal Peers
- 2023. Mechanisms of Bone Marrow Fibrosis in Myelofibrosis. Houston, TX, US.
- 2023. Neoplastic Fibrocytes: A Target for Therapy in Myelofibrosis. Houston, TX, US.
- 2023. Targeting neoplastic fibrocytes in myelofibrosis. Houston, TX, US.
- 2022. Central role of neoplastic monocyte-derived cells in the pathogenesis of myelofibrosis. Houston, TX, US.
- 2021. Role of neoplastic monocytes and T cells in the pathogenesis of PMF. Houston, TX, US.
- 2019. Update on classic myeloproliferative neoplasms: Fibrotic transformation. Houston, TX, US.
Grant & Contract Support
| Date: | 2025 - 2028 |
| Title: | Establishing an Integrated Multi-omic Hub for Advancing Myeloproliferative Neoplasm Research |
| Funding Source: | US Department of Defense |
| Role: | Co-I |
| ID: | GRANT14257354 (FP00024200) |
| Date: | 2025 - 2027 |
| Title: | Multimodal Proteomic and Single Cell Pathways in Systemic Mastocytosis |
| Funding Source: | US Department of Defense |
| Role: | Co-PI |
| ID: | GRANT14151649 (FP00022945) |
| Date: | 2025 - 2028 |
| Title: | Structural fingerprinting of TCR repertoires in leukemias |
| Funding Source: | Cancer Prevention and Research Institute of Texas |
| Role: | Co-I |
| ID: | FP00023128 |
| Date: | 2024 - 2025 |
| Title: | Development and Evaluation of Mutant-Selective JAK2 Inhibitors for Targeted Therapy in Myeloproliferative Neoplasms |
| Funding Source: | Prelude Therapeutics, Inc |
| Role: | PI |
| ID: | LS2024-00063978 |
| Date: | 2024 - 2026 |
| Title: | Decoding Immune Dysfunction to Target Progressive Bone Marrow Fibrosis in Myelofibrosis |
| Funding Source: | MPN Research Foundation |
| Role: | PI |
| ID: | FP00021829 |
| Date: | 2024 - 2029 |
| Title: | MYC Protein Degradation in TP53 mutant AML |
| Funding Source: | National Cancer Institute |
| Role: | Co-I |
| ID: | GRANT13906009 (FP00019780) |
| Date: | 2024 - 2027 |
| Title: | Investigating the Impact of Interferon Gamma Signaling on Therapeutic Resistance in Acute Myeloid Leukemia |
| Funding Source: | Cancer Prevention and Research Institute of Texas |
| Role: | Co-I |
| ID: | RP240287 (FP00019852) |
| Date: | 2024 - 2027 |
| Title: | Targeting of metabolic crosstalk between leukemia and macrophages as a therapeutic strategy for disease eradication and restoration of innate immune system |
| Funding Source: | Cancer Prevention and Research Institute of Texas |
| Role: | Co-I |
| ID: | RP240324 (FP00019895) |
| Date: | 2023 - 2025 |
| Title: | Role of the JAK-STAT pathway in the induction of osteosclerosis in myelofibrosis |
| Funding Source: | MPN Research Foundation |
| Role: | PI |
| ID: | FP00017401 |
| Date: | 2022 - 2024 |
| Title: | Nanoparticle-Mediated Targeting of Monocytes in Primary Myelofibrosis |
| Funding Source: | Avilect Biosciences, Inc. / Aviceda Therapeutics, Inc |
| Role: | PI |
| ID: | LS2022-00060725 |
| Date: | 2021 - 2022 |
| Title: | Role of the JAK-STAT Pathway in the Induction of Osteosclerosis in Myelofibrosis |
| Funding Source: | Baylor College of Medicine / MD Anderson Cancer Center / UTHealth Bone Disease Program of Texas |
| Role: | PI |
| ID: | FP00015007 |
Patient Reviews
CV information above last modified April 22, 2025